Detalles de la búsqueda
1.
Exploring the latent cognitive structure in schizophrenia: implications for antipsychotic treatment responses.
Eur Arch Psychiatry Clin Neurosci;
2024 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38801534
2.
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.
BMC Med;
21(1): 263, 2023 07 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37468932
3.
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.
BMC Psychiatry;
22(1): 210, 2022 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313842
4.
Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia.
Transl Psychiatry;
14(1): 79, 2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320995
5.
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Psychiatry Res;
322: 115138, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871411
6.
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.
Schizophr Bull;
48(4): 850-859, 2022 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35569003
7.
The effects of probiotics plus dietary fiber on antipsychotic-induced weight gain: a randomized clinical trial.
Transl Psychiatry;
12(1): 185, 2022 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35508529
8.
Altered regional homogeneity and cognitive impairments in first-episode schizophrenia: A resting-state fMRI study.
Asian J Psychiatr;
71: 103055, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35303593
9.
Corrigendum: The association between metabolic disturbance and cognitive impairments in early-stage schizophrenia.
Front Hum Neurosci;
16: 1094810, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36479428
10.
Identifying and revealing different brain neural activities of cognitive subtypes in early course schizophrenia.
Front Mol Neurosci;
15: 983995, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36267704
11.
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
Psychopharmacology (Berl);
239(1): 83-91, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35029705
12.
Internet addiction among teenagers in a Chinese population: Prevalence, risk factors, and its relationship with obsessive-compulsive symptoms.
J Psychiatr Res;
153: 134-140, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35810603
13.
Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine.
Front Pharmacol;
13: 935362, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36034782
14.
Corrigendum: The association between cognitive deficits and clinical characteristic in first-episode drug naïve patients with schizophrenia.
Front Psychiatry;
13: 1094791, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36601523
15.
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.
Psychopharmacology (Berl);
238(9): 2449-2457, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002246
16.
Dietary fiber and probiotics for the treatment of atypical antipsychotic-induced metabolic side effects: study protocol for a randomized, double-blind, placebo-controlled trial.
Trials;
22(1): 159, 2021 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-33622382
17.
Corrigendum: The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia.
Front Psychiatry;
12: 678836, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33967866
18.
The Association Between Cognitive Deficits and Clinical Characteristic in First-Episode Drug Naïve Patients With Schizophrenia.
Front Psychiatry;
12: 638773, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33716832
19.
Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial.
Front Psychiatry;
12: 611070, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33716817
20.
1-(2-Bromo-ethyl)-1,4-diazo-niabicyclo-[2.2.2]octane bromide dihydrogen phosphate-phospho-ric acid (1/1).
Acta Crystallogr Sect E Struct Rep Online;
66(Pt 6): o1339, 2010 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21579428